Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Immunitybio Inc (NQ: IBRX )

5.606 +0.276 (+5.18%)
Streaming Delayed Price Updated: 2:40 PM EDT, Jul 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,468,452
Open 5.340
Bid (Size) 5.600 (7)
Ask (Size) 5.610 (7)
Prev. Close 5.330
Today's Range 5.330 - 5.720
52wk Range 1.250 - 10.53
Shares Outstanding 391,156,513
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
7 Biotech Stocks to Keep on Your Clinical Radar
Biotech stocks have always been relevant. However, with the latest shift in the political race, this sector is bound to grab more eyeballs. 
Via InvestorPlace
3 Top Cancer Treatment Stocks to Buy Now
These cancer treatment stocks are well-positioned to benefit tremendously from strong demand for their cancer treatments in the longer term. 
Via InvestorPlace

Performance

YTD
+6.98%
+6.98%
1 Month
-23.62%
-23.62%
3 Month
+16.31%
+16.31%
6 Month
+73.83%
+73.83%
1 Year
+117.71%
+117.71%

More News

Read More
China's Bilibili And Ollie's Bargain Outlet Were Among 10 Mid Cap Stocks With Biggest Gains In The Last Week (June 16-June 22, 2024): Are They In Your Portfolio?
Via Benzinga
Why ImmunityBio Stock Is Trading Higher Thursday
Via Benzinga
KB Home Reports Upbeat Earnings, Joins Harrow, Accenture, Gilead Sciences And Other Big Stocks Moving Higher On Thursday
Via Benzinga
How Is The Market Feeling About ImmunityBio?
Via Benzinga
Check Out What Whales Are Doing With IBRX
Via Benzinga
Why Jabil Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
ImmunityBio Announces Insurance Coverage of ANKTIVA® Across Multiple States with First Commercial Doses Administered Just Weeks After FDA Approval—Opening New Era for Immunotherapy Beyond Checkpoint Inhibitors
From ImmunityBio, Inc.
Via Business Wire
3 Short-Squeeze Stocks Outwitting the Pessimistic Predictions
Via InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
ImmunityBio Announces 2024 Annual Meeting of Stockholders with Company Update
From ImmunityBio, Inc.
Via Business Wire
These 3 Interesting Stocks Are Seeing Heavy Short Interest In June 2024
Via Talk Markets
Connecting the Dots of ANKTIVA’s Triangle Offense: A Deep Dive with Dr. Patrick Soon-Shiong and Dr. Ashish Kamat in a Three-Part UroToday Podcast
From ImmunityBio, Inc.
Via Business Wire
Amid Biotech Pitfalls, ImmunityBio Has Outperformed NVDA In The Last 3 Months
Via Talk Markets
IBRX Stock Earnings: ImmunityBio Misses EPS, Beats Revenue for Q1 2024
Via InvestorPlace
The 3 Best Bargain Stocks to Buy in May 2024
Via InvestorPlace
Tempur Sealy Posts Upbeat Earnings, Joins FibroGen, Coca-Cola Consolidated, Fabrinet And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
ImmunityBio Completes GMP Drug Substance Manufacturing Sufficient for 170,000 Doses of ANKTIVA®
From ImmunityBio, Inc.
Via Business Wire
Even Worse than Gamestop? 3 Meme Stocks That Are Screaming Sells
Via InvestorPlace
Serum Institute of India Inks Large-Scale Supply Deal For BCG Use In ImmunityBio's Bladder Cancer Combo Therapy
Via Benzinga
Amgen Posts Upbeat Results, Joins OneSpan, Paylocity Holding, MercadoLibre And Other Big Stocks Moving Higher On Friday
Via Benzinga
ImmunityBio, Serum Institute of India Agree on an Exclusive Arrangement for Global Supply of Bacillus Calmette-Guerin (BCG) Across All Cancer Types
From ImmunityBio, Inc.
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
ImmunityBio Executive Chairman Dr. Patrick Soon-Shiong to Discuss ANKTIVA® Approval in Fireside Chat at the Annual Conference of the American Urological Association
From ImmunityBio, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.